SCHEMBL1852207

SCHEMBL1852207

NC(=O)C(Cl)c1c[nH]c2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.53
ATM Q13315 1/20 0.53
KMT2A Q03164 5/20 0.51
MEN1 O00255 4/20 0.51
HTR2A P28223 1/20 0.49
HTR2C P28335 1/20 0.49
HTR2B P41595 1/20 0.49
GPR84 Q9NQS5 4/20 0.49
FFAR1 O14842 2/20 0.49
MGAM O43451 3/20 0.48
GAA P10253 3/20 0.48
SI P14410 3/20 0.48
MGAM2 Q2M2H8 3/20 0.48
MAPT P10636 3/20 0.48
PKM P14618 1/20 0.48
STAT3 P40763 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
PBRM1 Q86U86 1/20 0.45
NOD2 Q9HC29 1/20 0.45
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9250842 0.85 KMT2A (0.56) ALDH1A1KMT2AMEN1GPR84FFAR1
SCHEMBL4001528 0.83 GPR84 (0.57) ALDH1A1ATMKMT2AMEN1HTR2A
SCHEMBL27586464 0.83 ALDH1A1 (0.56) ALDH1A1ATMKMT2AMEN1HTR2A
SCHEMBL29053760 0.82 GPR84 (0.56) ALDH1A1ATMKMT2AMEN1HTR2A
SCHEMBL2870565 0.81 ALDH1A1 (0.54) ALDH1A1ATMKMT2AMEN1HTR2A
SCHEMBL27155060 0.81 ALDH1A1 (0.54) ALDH1A1ATMKMT2AMEN1HTR2A
SCHEMBL2874859 0.80 ALDH1A1 (0.53) ALDH1A1ATMKMT2AMEN1HTR2A
SCHEMBL1854970 0.80 KMT2A (0.50) ALDH1A1KMT2AMEN1HTR2AHTR2C
SCHEMBL3334190 0.80 NR4A2 (0.53) ALDH1A1KMT2AMEN1HTR2AHTR2C
SCHEMBL1850845 0.80 NOD2 (0.51) ALDH1A1KMT2AMEN1HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110831943-B Method for producing piperazine rings for the synthesis of pyrazinocarbazole derivatives 社会医疗技术员技术股份公司 2022-05-03 CN disclosed
EP-3612534-B1 PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) 2021-12-22 EP disclosed
US-11008327-B2 Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) 2021-05-18 US disclosed
US-20200131186-A1 PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) 2020-04-30 US disclosed
EP-3612534-A1 PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES Tecnimede, Sociedade Técnico-Medicinal, SA (PT) 2020-02-26 EP disclosed
CN-110831943-A Method for producing piperazine rings for the synthesis of pyrazinocarbazole derivatives 社会医疗技术员技术股份公司 2020-02-21 CN disclosed
WO-2018193414-A1 PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) 2018-10-25 WO disclosed
EP-3392250-A1 PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES TECNIMEDE-SOCIEDADE TECNICO-MEDICINAL, S.A. (PT) 2018-10-24 EP disclosed
US-8242116-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-08-14 US disclosed
EP-2035436-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-05-25 EP disclosed
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-06-03 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071888-A1 PYRROLOTHIAZOLES AS PI3-KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2035436-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-18 EP disclosed
WO-2008001076-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11008327-B2 Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole PIR, DRD5, DRD1 ALDH1A1 1285/4885ATM 4471/4885KMT2A 4025/4885
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors PI4KA, PDPK1, PIK3CA ALDH1A1 2279/4885ATM 359/4885KMT2A 2966/4885
US-20200131186-A1 PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES PIR, CYP3A5, DRD5 ALDH1A1 1476/4885ATM 4172/4885KMT2A 2684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.